NIFTY23,4060.33%
SENSEX74,3460.41%
BANKNIFTY54,1860.88%
NIFTY IT29,3845.57%
PHARMA24,0870.33%
AUTO26,0930.05%
FMCG48,1241.01%
METAL13,5350.17%
REALTY762.601.39%
ENERGY40,1970.02%
NIFTY23,4060.33%
SENSEX74,3460.41%
BANKNIFTY54,1860.88%
NIFTY IT29,3845.57%
PHARMA24,0870.33%
AUTO26,0930.05%
FMCG48,1241.01%
METAL13,5350.17%
REALTY762.601.39%
ENERGY40,1970.02%

IBM Stock Plunges 13.2% on Anthropic's Claude Code Update

IBM shares fell to their lowest level in nearly three decades, dropping 13.2% to $223.35 per share on Monday, in response to an update from artificial intelligence company Anthropic regarding its Claude Code tool.

The decline marks IBM's worst day since 2000, as the AI startup revealed that Claude Code can now be used to automate the exploration and analysis of Cobol, a dated programming language that is run on IBM computers. Cobol is used to power critical systems in finance, airlines, and government, and Anthropic's update suggests that Claude Code can help modernize Cobol codebases.

Anthropic's blog post highlighted the potential of Claude Code to streamline tasks that have made Cobol modernization cost-prohibitive. The tool can map dependencies across thousands of lines of code, document workflows, and identify risks that would take human analysts months to surface. This news has sparked fears that artificial intelligence will disrupt the growth of big tech companies, with IBM being the latest victim.

Read also: Treasury Yields Experience Largest Increase in Two Weeks Following Release of Labor Market Data

IBM's mainframe business remains a significant contributor to its revenue, with many customers relying on these massive servers to run applications on Cobol. The company's shares have fallen 27% in February, on track for its biggest one-month slide since at least 1968, according to data compiled by Bloomberg.

Investor Takeaway

Investors should be cautious of the impact of AI-powered tools on traditional tech stocks.

IPOScanner Logo

IPOScanner helps investors track upcoming, live and past IPOs in one place with GMP, subscription, allotment status and listing performance insights.

About IPO Scanner

IPOScanner is built for investors who want a clear view of every IPO opportunity in one place. From upcoming issues to live subscription data, allotment updates and listing performance, we bring together the key details you need to track the primary market.

Our tools are designed to be simple, fast and investor-friendly so you can focus on evaluating businesses instead of opening multiple tabs and websites for basic information.

Details of client bank account
For any query / feedback / clarifications, email at
[email protected].

Please read all offer documents and risk disclosures carefully before investing. IPOScanner does not provide investment advice and information on this site should not be treated as a recommendation to apply for any IPO.

© 2026 IPO Scanner. All rights reserved.